J Pharm Pharmacogn Res 3(suppl. 1): S45, 2015
Proceedings of the 4th International Symposium on Pharmacology of Natural Products FAPRONATURA 2015 September 21st-25th, 2015; Cuban Society of Pharmacology. Topes de Collantes, Sancti Spiritus, Cuba.
OC-26: OLEOZON IN THE TREATMENT OF Giardia lamblia IN CHILDHOOD
Herrero H, Casas S, Ramos L, Gross C.
Introduction: Giardiasis is one of the most common infections produced by intestinal protozoans worlwide. It provokes serious health problems due to the quantity of symptoms that accompany the infection. Due to the adverse effects and the treatment failure with some medicines is recommended the use of natural products such as ozoneficated girasol oil (OLEOZON), because of its extraordinary germicidal action. Methods: For that reason, and taking into consideration these aspects, we did a clinic controlled study (quasi-experimental) with the objective to evaluate to the effectiveness of oral OLEOZON in the treatment of Giardia lamblia in children attended the pediatric interconsult in the Policlinic Julián Grimau in Santiago de Cuba during the period from January to December 2014. The universe was constituted by 58 patients (cases and controls) with the diagnosis of giardiasis, which present as main symptoms abdominal pain, vomit and anorexia. The results were statistically validated by SSPS version 11.5. Results: The main results revealed were that the major number of patients showed a relief concerning the abdominal pain and in general, the symptomatology decrease, furthermore the treatment result less expensive and without adverse reactions reported. There is also a positive impact from the economical, social and environmental point of view. Conclusions: OLEOZON proved to be an effective therapeutic for the treatment Giardia lamblia in childhood.
Citation Format: Herrero H, Casas S, Ramos L, Gross C (2015) OLEOZON in the treatment of Giardia lamblia in childhood. [Abstract]. In: Proceedings of the FAPRONATURA 2015; 2015 Sep 21-25; Topes de Collantes, Sancti Spiritus: CSF. J Pharm Pharmacogn Res 3(Suppl. 1): S45. Abstract nr OC-26.